Stay updated on Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial

Sign up to get notified when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The site footer revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T19:25:05.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology during the transition period.
    Difference
    1%
    Check dated 2026-10-24T19:34:59.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T19:44:20.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer site revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T20:24:51.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The study record area displays a 403 Forbidden message and a Home link instead of study details.
    Difference
    0.5%
    Check dated 2026-10-03T19:36:42.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, indicating access to the study record is blocked. This reflects a site access issue rather than a substantive update to the study content.
    Difference
    17%
    Check dated 2026-09-19T19:05:43.000Z thumbnail image

Stay in the know with updates to Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cofetuzumab Pelidotin in PTK7+ NSCLC: Efficacy and Safety Clinical Trial page.